Stock listing
A0DNPW Stock Price, News, Filings & Events — Mesoblast Limited
Selected listing: A0DNPW · LSX · EUR · DE
This page tracks Mesoblast Limited's A0DNPW:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A0DNPW:LSX. A0DNPW:LSX is the stock-level entry point for investors researching Mesoblast Limited, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A0DNPW:LSX
- Asset type
- Stock
- Market cap
- $2.32B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- LSX
- Currency
- EUR
Mesoblast Limited A0DNPW:LSX stock context
This page tracks Mesoblast Limited's A0DNPW:LSX listing on LSX in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A0DNPW:LSX. A0DNPW:LSX is the stock-level entry point for investors researching Mesoblast Limited, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Mesoblast Limited
Mesoblast Reports Substantial Revenue Growth to US$120M
August 26, 2026
Major Milestone Treatment Completed in P3 Trial for CLBP
August 16, 2026
Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch
July 29, 2026
Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
July 13, 2026
Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
July 9, 2026
Research Mesoblast Limited
Mesoblast Limited investor report
Review AI stock analysis and investor report context for A0DNPW:LSX.
Mesoblast Limited company profile
View the public company page for Mesoblast Limited on 6ix.
Mesoblast Limited news
Read company news and market updates connected to Mesoblast Limited.
Mesoblast Limited investor events
Find investor webinars, events, and replay context for Mesoblast Limited.
Alternate listings
MSB:ASX
AU · AUD
Alternate listing for Mesoblast Limited; the primary context on this page is A0DNPW:LSX.
MESO:NASDAQ
US · USD
Alternate listing for Mesoblast Limited; the primary context on this page is A0DNPW:LSX.
LWB:GETTEX
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is A0DNPW:LSX.
MEOBF:OTC
US · USD
Alternate listing for Mesoblast Limited; the primary context on this page is A0DNPW:LSX.
A0DNPW:LS
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is A0DNPW:LSX.
MESO:BOATS
US · USD
Alternate listing for Mesoblast Limited; the primary context on this page is A0DNPW:LSX.
LWB1:GETTEX
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is A0DNPW:LSX.
LWB:TRADEGATE
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is A0DNPW:LSX.
LWB:FWB
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is A0DNPW:LSX.
LWB:BX
CH · CHF
Alternate listing for Mesoblast Limited; the primary context on this page is A0DNPW:LSX.
LWB:DUS
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is A0DNPW:LSX.
LWB1:FWB
DE · EUR
Alternate listing for Mesoblast Limited; the primary context on this page is A0DNPW:LSX.